Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASAP OTCMKTS:INNI OTCMKTS:IVFZF OTCMKTS:USRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASAPWaitr$0.00$0.01▼$0.35$237K0.6671,203 shsN/AINNIInnovaro$0.01$0.01$0.00▼$0.02$226K45.9814,493 shsN/AIVFZFMapath Capital$0.01$0.01$0.01▼$0.01$248K-0.03N/AN/AUSRMBioheart$0.00$0.00$0.00▼$0.00N/A-1.35227,315 shs2,375 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASAPWaitr0.00%0.00%0.00%0.00%+127.27%INNIInnovaro0.00%0.00%-0.99%-1.96%-45.65%IVFZFMapath Capital0.00%0.00%0.00%+90.00%+9,400.00%USRMBioheart0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASAPWaitrN/AN/AN/AN/AN/AN/AN/AN/AINNIInnovaroN/AN/AN/AN/AN/AN/AN/AN/AIVFZFMapath CapitalN/AN/AN/AN/AN/AN/AN/AN/AUSRMBioheartN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASAPWaitr 0.00N/AN/AN/AINNIInnovaro 0.00N/AN/AN/AIVFZFMapath Capital 0.00N/AN/AN/AUSRMBioheart 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASAPWaitr$130.00M0.00N/AN/A($2.86) per share0.00INNIInnovaroN/AN/AN/AN/AN/AN/AIVFZFMapath CapitalN/AN/AN/AN/AN/AN/AUSRMBioheart$80KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASAPWaitr-$206.79MN/A0.00N/AN/A-111.96%N/A-209.50%N/AINNIInnovaro-$10KN/A0.00∞N/AN/AN/AN/AN/AIVFZFMapath Capital-$90KN/A0.00∞N/AN/AN/A-630.21%N/AUSRMBioheart-$2.86MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASAPWaitrN/AN/AN/AN/AN/AINNIInnovaroN/AN/AN/AN/AN/AIVFZFMapath CapitalN/AN/AN/AN/AN/AUSRMBioheartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASAPWaitrN/A0.140.14INNIInnovaroN/AN/AN/AIVFZFMapath CapitalN/AN/AN/AUSRMBioheartN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASAPWaitr0.04%INNIInnovaroN/AIVFZFMapath CapitalN/AUSRMBioheartN/AInsider OwnershipCompanyInsider OwnershipASAPWaitr14.20%INNIInnovaro3.30%IVFZFMapath Capital18.10%USRMBioheart16.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASAPWaitr84013.55 million11.62 millionNo DataINNIInnovaro722.61 million21.87 millionNot OptionableIVFZFMapath CapitalN/A26.12 million21.40 millionNot OptionableUSRMBioheart11N/AN/ANot OptionableUSRM, IVFZF, ASAP, and INNI HeadlinesRecent News About These CompaniesKennedy Says ‘Charlatans’ Are No Reason to Block Unproven Stem Cell TreatmentsJune 5, 2025 | nytimes.comThe Allure of Stem Cell TherapyJune 5, 2025 | nytimes.comHow our bones are repaired by skeletal stem cells: Scientist discover four major subtypesJune 4, 2025 | msn.comFirst Stem Cell Nerve Therapy Meant to Reverse Paralysis Enters Clinical TrialMay 28, 2025 | msn.comVascularized stem cell islet organoids offer improved model for diabetes researchMay 23, 2025 | msn.comFirst successful allogeneic stem cell transplant using deceased donor in blood cancer clinical trialMay 17, 2025 | sciencex.comSStem cells coaxed into most advanced amniotic sacs ever grown in the labMay 15, 2025 | nature.comNNewly discovered ‘super stem cells’ can transform into better versions of themselvesMay 7, 2025 | bgr.comBUltrasound and microrobots team up to boost stem cell therapy for brain repairApril 30, 2025 | msn.comA dangerous new push to ban embryonic stem cell research funding is gaining momentumApril 30, 2025 | statnews.comSFederal Circuit Affirms Stem Cell Product-by-Process Claims: Lessons in Claim Construction and Inherency from Restem LLV v. Jadi Cell LLCApril 25, 2025 | jdsupra.comDespite political pushback, the Yale Stem Cell Center has emerged as a leader in regenerative medicineApril 25, 2025 | yaledailynews.comYNew approach targets cell surface protein to treat leukemia and solid tumorsApril 24, 2025 | msn.comDNA organization offers clues for advancing stem cell therapyApril 17, 2025 | news.ucr.eduNNeural stem cells outside the brain: Discovery opens new paths for regenerative medicineApril 10, 2025 | msn.comWorld’s first human trial of sperm stem cell therapy aims to reverse male infertilityApril 7, 2025 | msn.comDrug-delivering aptamers target leukemia stem cells for a one-two knockout punchApril 3, 2025 | msn.comSperm Stem Cells Were Used for the First Time in an Attempt to Restore FertilityMarch 28, 2025 | wired.comWParalysed man stands again after receiving ‘reprogrammed’ stem cellsMarch 24, 2025 | nature.comNScientists create universal vascular graft with stem cells to improve surgery for cardiovascular diseaseMarch 10, 2025 | msn.comMedia Sentiment Over TimeUSRM, IVFZF, ASAP, and INNI Company DescriptionsWaitr NASDAQ:ASAPWaitr Holdings Inc. operates an online ordering technology platform in the United States. Its platform allows to order food, alcohol, convenience, grocery, flowers, auto parts, and others. The company's platform also facilitates access to third parties that provide payment processing solutions for restaurants and other merchants. Waitr Holdings Inc. was founded in 2013 and is headquartered in Lafayette, Louisiana.Innovaro OTCMKTS:INNI$0.01 0.00 (0.00%) As of 07/11/2025Innovaro, Inc. does not have significant operations. The company plans to acquire an operating company through reverse merger. Previously, it was engaged in the provision of software services. The company was formerly known as UTEK Corporation and changed its name to Innovaro, Inc. in July 2010. Innovaro, Inc. was incorporated in 1999 and is based in Smyrna, Delaware.Mapath Capital OTCMKTS:IVFZF$0.0095 0.00 (0.00%) As of 07/14/2025Mapath Capital Corp. does not have significant operations. The company is seeking for business opportunities. Previously, it was engaged in the provision of financial internet solutions, and tools content and services. The company was formerly known as Invictus Financial Inc. and changed its name to Mapath Capital Corp. in December 2022. Mapath Capital Corp. is based in Vancouver, Canada.Bioheart OTCMKTS:USRM$0.0001 0.00 (0.00%) As of 07/15/2025 01:23 PM EasternU.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
